BCRX Price Prediction Next Week
Analysis and Insights
Technical Analysis:
BioCryst Pharmaceuticals (BCRX) is currently trading near the lower end of its Bollinger Bands, suggesting potential oversold conditions. The stock closed at $8.05 on March 24, 2025, with a 52-week range of $4.03 to $9.50. The MACD is slightly negative, indicating bearish momentum, but the RSI of 51.22 suggests the stock is not deeply oversold.
Fundamental Analysis:
Recent news includes the resignation of CFO Anthony Doyle, which may have caused short-term volatility. However, analysts have maintained a positive outlook, with JMP Securities reiterating a Buy rating and a $18.00 price target. The average analyst price target is $14.73, indicating significant upside potential.
Analyst Sentiment:
Analysts remain bullish on BCRX, with a Strong Buy consensus rating. JMP Securities and Wedbush have recently reiterated their Buy ratings, reflecting confidence in the company's pipeline and growth prospects.
Price Prediction:
Based on the technical and fundamental analysis, BCRX is expected to rebound from its current levels. The stock is likely to test the $8.50 level next week, with a potential upside to $9.03. A stop-loss at $7.30 is recommended to manage risk.
Recommendation:
Buy BCRX with a target price of $8.50 and a stop-loss at $7.30.
BCRX Similar Chart Price Prediction
The price of BCRX is predicted to go up -36.05%, based on the high correlation periods with BLUE. The similarity of these two price pattern on the periods is 97.4%.
BCRX
BLUE
Down: -36.05%Similarity: 97.4%
BCRX Revenue Forecast
BCRX EPS Forecast
BCRX FAQs
What is BCRX revenue forecast for next quarter？
What is BCRX eps forecast for next quarter？
BCRX Analyst's Forecast
Gena Wang
Barclays
Hold
2024-11-05
Price Target
$7 → $8
Upside
+12.68%
Barclays raised the firm's price target on BioCryst to $8 from $7 and keeps an Equal Weight rating on the shares post the Q3 report. Orladeyo's Q3 revenue was a modest beat and the company's 2024 revenue guidance was narrowed to the upper end of tee range, the analyst tells investors in a research note.
